Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach
Open Access
- 5 February 2014
- journal article
- review article
- Published by Springer Nature in Radiation Oncology
- Vol. 9 (1) , 45
Abstract
Gastroesophageal cancers (such as esophageal, gastric and gastroesophageal-junction -GEJ- lesions) are worldwide a leading cause of death being relatively rare but highly aggressive. In the past years, a clear shift in the location of upper gastrointestinal tract tumors has been recorded, both affecting the scientific research and the modern clinical practice. The integration of pre- or peri-operative multimodal approaches, as radiotherapy and chemotherapy (often combined), seems promising to further improve clinical outcome for such presentations. In the past, the definition of GEJ led to controversies and confusion: GEJ tumors have been managed either grouped to gastric or esophageal lesions, following slightly different surgical, radiotherapeutic and systemic approaches. Recently, the American Joint Committee on Cancer (AJCC) changed the staging and classification system of GEJ to harmonize some staging issues for esophageal and gastric cancer. This review discusses the most relevant historical and recent evidences of neoadjuvant treatment involving Radiotherapy for GEJ tumors, and describes the efficacy of such treatment in the frame of multimodal integrated therapies, from the new point of view of the recent classification of such tumors.Keywords
This publication has 62 references indexed in Scilit:
- Genetic Polymorphisms at TIMP3 Are Associated with Survival of Adenocarcinoma of the Gastroesophageal JunctionPLOS ONE, 2013
- Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junctionBMC Cancer, 2013
- Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinomaBritish Journal of Cancer, 2011
- Long-term Outcome of 2920 Patients With Cancers of the Esophagus and Esophagogastric JunctionAnnals of Surgery, 2011
- Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trialEuropean Journal of Cancer, 2011
- Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Adenocarcinoma of the Esophagogastric Junction: Surgical Therapy Based on 1602 Consecutive Resected PatientsSurgical Oncology Clinics of North America, 2006
- Continuing rising trend in oesophageal adenocarcinomaInternational Journal of Cancer, 2002
- D2 dissection for gastric cancerSurgical Oncology, 1997